Restenosis Does Not Seem as Benign as We Thought

Elective, uncomplicated repeat revascularization after stent restenosis is associated with higher mortality rates according to a new meta-analysis that will be published soon in J Am Coll Cardiol Intrv.

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíacaHistorically, interventional cardiologists have seen target lesion revascularization (TLR) as a procedure that “unjustly” increased combined events in clinical studies and our own databases, thus representing a disadvantage for us against surgeons. Many people thought that if patients who underwent TLR did not go into cardiac arrest or die, this event only entailed the nuisance of having to return to the cath lab. This work forces us to start thinking that repeat revascularization is not entirely benign.

 

In a pooled analysis of 21 randomized trials that included 32,882 patients, repeat revascularization was an independent predictor of all-cause mortality after adjusting for potential confounding variables (hazard ratio [HR]: 1.23; 95% confidence interval [CI]: 1.04-1.45).


Read also: A mayor nivel de LDL, mayor beneficio en mortalidad con la terapia agresiva.


Even uncomplicated TLR procedures, in which the diagnosis of restenosis resulted from symptoms of effort or a routine study (as opposed to acute coronary syndrome), were still associated with an increased risk of long-term mortality. In that sense, stent restenosis might compete with de novo lesions as regards risk.

 

In this cohort, 7.2% of patients underwent an elective, uncomplicated target lesion repeat revascularization procedure at a mean of 271 days after the index angioplasty procedure. Comparatively, among the same cohort, 2.5% of patients underwent elective, uncomplicated revascularization of lesions non-related to the one previously treated.

 

Patients with restenosis were younger, more likely to be female, and more likely to have diabetes and other comorbidities than patients who underwent non-TLR revascularization.


Read also: Revascularización híbrida o cirugía convencional, la historia todavía se está escribiendo.


Mortality among patients who did not require a trip back to the cath lab was 1.87 per 100 patient-years, while among patients with restenosis it was 2.45 per 100 patient-years, and among patients with de novo lesions it was 2.67 per 100 patient-years.

 

After adjusting for multiple confounders, revascularization due to restenosis was associated with an increased risk of death whereas revascularization of de novo lesions was not.

 

Patients with restenosis who experienced an acute myocardial infarction sometime during follow-up had a fourfold higher risk of death (HR: 3.82; 95% CI: 2.44-5.99).


Read also: La hipertensión pulmonar basal pre-TAVI no debe contraindicar el procedimiento.


Additionally, researchers excluded from this analysis target lesion revascularizations presented as acute myocardial infarctions and patients who presented peri-procedural infarctions; in consequence, mortality might actually be underestimated.

 

Perhaps, patients with restenosis are more complex than others (whether from a clinical viewpoint, an anatomical viewpoint, or both), and that is what ultimately contributes to their worse prognosis.

 

Original title: Mortality Following Non-Emergent, Uncomplicated Target Lesion Revascularization After PCI: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients.

Reference: Palmerini T. et al. J Am Coll Cardiol Intrv. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...